公开(公告)号：US20170298020A1

公开(公告)日：2017-10-19

申请号：US15631796

申请日：2017-06-23

申请人： UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

发明人： B. Therese Kinsella ,  Helen Reid

IPC分类号： C07D213/71 ,  C07D305/08 ,  C07D295/192 ,  C07D277/34 ,  C07D261/08 ,  A61K31/18 ,  C07D231/12 ,  C07D213/85 ,  C07D213/34 ,  C07D205/04 ,  C07D307/42 ,  C07D263/48

摘要： The invention generally relates to methods and compounds for treating proliferative disorders, viral infections, or both. In some embodiments, the invention provides an anticancer or antiviral compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating a proliferative disorder or a viral infection including administering an anticancer or antiviral compound that binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

公开(公告)号：US09718781B2

公开(公告)日：2017-08-01

申请号：US14391917

申请日：2013-04-17

申请人： University College Dublin, National University of Ireland, Dublin

发明人： B. Therese Kinsella ,  Helen Reid

IPC分类号： A61K31/18 ,  C07D213/71 ,  C07D231/12 ,  C07D261/08 ,  C07D307/42 ,  C07D213/34 ,  C07D277/34 ,  C07D295/192 ,  C07D263/48 ,  C07D305/08 ,  C07D205/04 ,  C07D213/85

CPC分类号： C07D213/71 ,  A61K31/136 ,  A61K31/18 ,  A61K31/215 ,  A61K31/216 ,  A61K31/64 ,  C07C311/58 ,  C07C311/59 ,  C07C2601/14 ,  C07D205/04 ,  C07D213/34 ,  C07D213/53 ,  C07D213/85 ,  C07D213/89 ,  C07D231/12 ,  C07D261/08 ,  C07D263/48 ,  C07D277/34 ,  C07D295/192 ,  C07D305/08 ,  C07D307/42 ,  C07D307/52 ,  A61K2300/00

摘要： The invention generally relates to methods and compounds for treating proliferative disorders, viral infections, or both. In some embodiments, the invention provides an anticancer or antiviral compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating a proliferative disorder or a viral infection including administering an anticancer or antiviral compound that binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

公开(公告)号：US09388127B2

公开(公告)日：2016-07-12

申请号：US14391856

申请日：2013-04-17

申请人： University College Dublin, National University of Ireland, Dublin

发明人： B. Therese Kinsella ,  Patrick Guiry ,  Helen Reid ,  Barry O'Connor

IPC分类号： C07C311/58 ,  A61K31/215 ,  A61K31/64 ,  C07C311/59 ,  C07D205/04 ,  C07D213/53 ,  C07D213/71 ,  C07D213/89 ,  C07D231/12 ,  C07D261/08 ,  C07D263/48 ,  C07D277/34 ,  C07D295/192 ,  C07D305/08 ,  C07D307/52

CPC分类号： C07D213/71 ,  A61K31/18 ,  A61K31/215 ,  A61K31/64 ,  C07C311/58 ,  C07C311/59 ,  C07C2601/14 ,  C07D205/04 ,  C07D213/34 ,  C07D213/53 ,  C07D213/85 ,  C07D213/89 ,  C07D231/12 ,  C07D261/08 ,  C07D263/48 ,  C07D277/34 ,  C07D295/192 ,  C07D305/08 ,  C07D307/42 ,  C07D307/52 ,  A61K2300/00

摘要： The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

摘要翻译： 本发明一般涉及用作治疗血栓形成和其它心血管，肾或肺部疾病的TP拮抗剂的化合物。 在一些实施方案中，本发明提供了包含取代的硝基苯氧基苯基，磺酰脲和烷基的化合物。 在一些实施方案中，本发明提供了通过施用优先与血栓素受体结合的抗血栓形成化合物治疗血栓形成的方法，具有TPalpha（TPα）或TPbeta（TP＆bgr）受体亚型的优先结合。

公开(公告)号：US20160016900A1

公开(公告)日：2016-01-21

申请号：US14391856

申请日：2013-04-17

申请人： University College Dublin, National University of Ireland, Dublin

发明人： B. Therese Kinsella ,  Patrick Guiry ,  Helen Reid ,  Barry O'Connor

IPC分类号： C07C311/58 ,  C07D231/12 ,  C07D261/08 ,  C07D307/52 ,  C07D213/53 ,  C07D213/89 ,  C07D295/192 ,  C07D205/04 ,  C07D305/08 ,  C07D263/48 ,  C07C311/59 ,  C07D213/71 ,  C07D277/34

CPC分类号： C07D213/71 ,  A61K31/18 ,  A61K31/215 ,  A61K31/64 ,  C07C311/58 ,  C07C311/59 ,  C07C2601/14 ,  C07D205/04 ,  C07D213/34 ,  C07D213/53 ,  C07D213/85 ,  C07D213/89 ,  C07D231/12 ,  C07D261/08 ,  C07D263/48 ,  C07D277/34 ,  C07D295/192 ,  C07D305/08 ,  C07D307/42 ,  C07D307/52 ,  A61K2300/00

摘要： The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

摘要翻译： 本发明一般涉及用作治疗血栓形成和其它心血管，肾或肺部疾病的TP拮抗剂的化合物。 在一些实施方案中，本发明提供了包含取代的硝基苯氧基苯基，磺酰脲和烷基的化合物。 在一些实施方案中，本发明提供了通过施用优先与血栓素受体结合的抗血栓形成化合物治疗血栓形成的方法，具有TPalpha（TPα）或TPbeta（TP＆bgr）受体亚型的优先结合。

公开(公告)号：US09738599B2

公开(公告)日：2017-08-22

申请号：US15460910

申请日：2017-03-16

申请人： UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

发明人： B. Therese Kinsella ,  Patrick Guiry ,  Helen Reid ,  Barry O'Connor

IPC分类号： C07C311/58

CPC分类号： C07D213/71 ,  A61K31/18 ,  A61K31/215 ,  A61K31/64 ,  C07C311/58 ,  C07C311/59 ,  C07C2601/14 ,  C07D205/04 ,  C07D213/34 ,  C07D213/53 ,  C07D213/85 ,  C07D213/89 ,  C07D231/12 ,  C07D261/08 ,  C07D263/48 ,  C07D277/34 ,  C07D295/192 ,  C07D305/08 ,  C07D307/42 ,  C07D307/52 ,  A61K2300/00

摘要： The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

公开(公告)号：US20160280640A1

公开(公告)日：2016-09-29

申请号：US15178931

申请日：2016-06-10

申请人： UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

发明人： B. Therese Kinsella ,  Patrick Guiry ,  Helen Reid ,  Barry O'Connor

IPC分类号： C07C311/58

CPC分类号： C07D213/71 ,  A61K31/18 ,  A61K31/215 ,  A61K31/64 ,  C07C311/58 ,  C07C311/59 ,  C07C2601/14 ,  C07D205/04 ,  C07D213/34 ,  C07D213/53 ,  C07D213/85 ,  C07D213/89 ,  C07D231/12 ,  C07D261/08 ,  C07D263/48 ,  C07D277/34 ,  C07D295/192 ,  C07D305/08 ,  C07D307/42 ,  C07D307/52 ,  A61K2300/00

摘要： The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

摘要翻译： 本发明一般涉及用作治疗血栓形成和其它心血管，肾或肺部疾病的TP拮抗剂的化合物。 在一些实施方案中，本发明提供了包含取代的硝基苯氧基苯基，磺酰脲和烷基的化合物。 在一些实施方案中，本发明提供了通过施用优先与血栓烷受体结合的抗血栓形成化合物治疗血栓形成的方法，具有TPalpha（TPα）或TPβ（TPβ）受体亚型的优先结合。

公开(公告)号：US09932304B2

公开(公告)日：2018-04-03

申请号：US15180805

申请日：2016-06-13

申请人： UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

发明人： B. Therese Kinsella ,  Helen Reid

IPC分类号： C07C311/58

CPC分类号： C07C311/58

摘要： The invention relates to novel chemical entities that act as thromboxane (TX) A2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents that act as incidental ligands of TP, including the endoperoxide prostaglandin (PG)G2/PGH2, 20-hydroxyeicosatetraenoic acid (20-HETE) and the free-radical derived isoprostanes (e.g., 8-iso-prostaglandin (PG)F2α), play a role. Compounds of the invention preferably include a benzenesulfonyl urea in which the benzene is substituted by a substituted biphenylyloxy group (e.g., at the 2 position) and by a nitrile group (e.g., at the 5 position), which compounds show promising results as TP-isoform selective TP antagonists.

公开(公告)号：US09630915B2

公开(公告)日：2017-04-25

申请号：US15349379

申请日：2016-11-11

申请人： UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

发明人： B. Therese Kinsella ,  Patrick Guiry ,  Helen Reid ,  Barry O'Connor

IPC分类号： C07C311/58

CPC分类号： C07D213/71 ,  A61K31/18 ,  A61K31/215 ,  A61K31/64 ,  C07C311/58 ,  C07C311/59 ,  C07C2601/14 ,  C07D205/04 ,  C07D213/34 ,  C07D213/53 ,  C07D213/85 ,  C07D213/89 ,  C07D231/12 ,  C07D261/08 ,  C07D263/48 ,  C07D277/34 ,  C07D295/192 ,  C07D305/08 ,  C07D307/42 ,  C07D307/52 ,  A61K2300/00

摘要： The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

公开(公告)号：US09522877B2

公开(公告)日：2016-12-20

申请号：US15178931

申请日：2016-06-10

申请人： UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

发明人： B. Therese Kinsella ,  Patrick Guiry ,  Helen Reid ,  Barry O'Connor

IPC分类号： C07C311/58

CPC分类号： C07D213/71 ,  A61K31/18 ,  A61K31/215 ,  A61K31/64 ,  C07C311/58 ,  C07C311/59 ,  C07C2601/14 ,  C07D205/04 ,  C07D213/34 ,  C07D213/53 ,  C07D213/85 ,  C07D213/89 ,  C07D231/12 ,  C07D261/08 ,  C07D263/48 ,  C07D277/34 ,  C07D295/192 ,  C07D305/08 ,  C07D307/42 ,  C07D307/52 ,  A61K2300/00

摘要： The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

摘要翻译： 本发明一般涉及用作治疗血栓形成和其它心血管，肾或肺部疾病的TP拮抗剂的化合物。 在一些实施方案中，本发明提供了包含取代的硝基苯氧基苯基，磺酰脲和烷基的化合物。 在一些实施方案中，本发明提供了通过施用优先与血栓烷受体结合的抗血栓形成化合物治疗血栓形成的方法，具有TPalpha（TPα）或TPβ（TPβ）受体亚型的优先结合。

公开(公告)号：US20190336513A1

公开(公告)日：2019-11-07

申请号：US16517947

申请日：2019-07-22

申请人： UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

发明人： B. Therese Kinsella ,  Helen Reid

IPC分类号： A61K31/64 ,  C07C311/58

摘要： The invention relates to novel chemical entities that act as thromboxane (TX) A2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents that act as incidental ligands of TP, including the endoperoxide prostaglandin (PG)G2/PGH2, 20-hydroxyeicosatetraenoic acid (20-HETE) and the free-radical derived isoprostanes (e.g., 8-iso-prostaglandin (PG)F2α), play a role. Compounds of the invention preferably include a benzenesulfonyl urea in which the benzene is substituted by a substituted biphenylyloxy group (e.g., at the 2 position) and by a nitrile group (e.g., at the 5 position), which compounds show promising results as TP-isoform selective TP antagonists.